Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
12.53
+0.20 (1.62%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Y-mAbs Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 84.5 | 84.82 | 65.27 | 34.9 | 20.75 | - | Upgrade
|
| Revenue Growth (YoY) | 12.62% | 29.96% | 87.03% | 68.18% | - | - | Upgrade
|
| Cost of Revenue | 11.48 | 11.42 | 7.57 | 2.51 | 2.2 | - | Upgrade
|
| Gross Profit | 73.02 | 73.4 | 57.7 | 32.38 | 18.55 | - | Upgrade
|
| Selling, General & Admin | 44.7 | 44.5 | 52.47 | 56.94 | 45.9 | 20.01 | Upgrade
|
| Research & Development | 53.4 | 50.09 | 88.55 | 90.88 | 92.58 | 63 | Upgrade
|
| Operating Expenses | 98.1 | 94.59 | 141.02 | 147.82 | 138.48 | 83 | Upgrade
|
| Operating Income | -25.08 | -21.19 | -83.32 | -115.43 | -119.94 | -83 | Upgrade
|
| Interest Expense | - | - | - | -1.85 | - | - | Upgrade
|
| Interest & Investment Income | 4.13 | 4.81 | 0.64 | - | 0.02 | 2.02 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0.58 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -20.95 | -16.38 | -82.68 | -117.29 | -119.34 | -81.03 | Upgrade
|
| Merger & Restructuring Charges | - | -4.48 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 62.01 | - | - | Upgrade
|
| Asset Writedown | - | - | -0.62 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -12.28 | - | - | - | Upgrade
|
| Pretax Income | -20.95 | -20.87 | -95.57 | -55.28 | -119.34 | -81.03 | Upgrade
|
| Income Tax Expense | 0.72 | 0.56 | - | - | - | - | Upgrade
|
| Net Income | -21.67 | -21.43 | -95.57 | -55.28 | -119.34 | -81.03 | Upgrade
|
| Net Income to Common | -21.67 | -21.43 | -95.57 | -55.28 | -119.34 | -81.03 | Upgrade
|
| Shares Outstanding (Basic) | 44 | 44 | 44 | 43 | 40 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 44 | 44 | 44 | 43 | 40 | 35 | Upgrade
|
| Shares Change (YoY) | -0.05% | -0.13% | 1.21% | 7.64% | 14.03% | 22.28% | Upgrade
|
| EPS (Basic) | -0.50 | -0.49 | -2.19 | -1.28 | -2.97 | -2.30 | Upgrade
|
| EPS (Diluted) | -0.50 | -0.49 | -2.19 | -1.28 | -2.97 | -2.30 | Upgrade
|
| Free Cash Flow | -17.59 | -27.23 | -75.92 | -103.22 | -91.41 | -75.46 | Upgrade
|
| Free Cash Flow Per Share | -0.40 | -0.62 | -1.74 | -2.39 | -2.28 | -2.14 | Upgrade
|
| Gross Margin | 86.41% | 86.54% | 88.41% | 92.80% | 89.38% | - | Upgrade
|
| Operating Margin | -29.68% | -24.98% | -127.66% | -330.78% | -578.00% | - | Upgrade
|
| Profit Margin | -25.64% | -25.26% | -146.43% | -158.39% | - | - | Upgrade
|
| Free Cash Flow Margin | -20.81% | -32.11% | -116.32% | -295.79% | -440.51% | - | Upgrade
|
| EBITDA | -24.37 | -20.46 | -82.48 | -114.65 | -119.54 | -82.84 | Upgrade
|
| EBITDA Margin | -28.84% | -24.12% | -126.37% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.71 | 0.74 | 0.84 | 0.78 | 0.4 | 0.17 | Upgrade
|
| EBIT | -25.08 | -21.19 | -83.32 | -115.43 | -119.94 | -83 | Upgrade
|
| EBIT Margin | -29.68% | -24.98% | -127.66% | - | - | - | Upgrade
|
| Revenue as Reported | 84.5 | 84.82 | 65.27 | 34.9 | 20.75 | - | Upgrade
|
Source: S&P Capital IQ. Standard template.